Results 51 to 60 of about 414,323 (331)

Day/night variations of myeloid and lymphoid cell subsets in the murine inguinal lymph node

open access: yesFEBS Open Bio, EarlyView.
The circadian system is involved in the temporal regulation of the immune system. Our study reveals that two innate immune populations, NKT cells and neutrophils, predominate at the beginning of the day in healthy mice, highlighting how the time of day influences immune responses.
Paula M. Wagner   +6 more
wiley   +1 more source

Structure-function relations in phosphorylcholine-binding mouse myeloma proteins [PDF]

open access: yes, 1977
The binding site interactions between the phosphorylcholine (phosphocholine)-binding mouse myeloma proteins TEPC 15, W3207, McPC 603, MOPC 167, and MOPC 511 and the isotopically substituted hapten phosphoryl-[methyl-13C]choline have been investigated ...
Goetze, Andrew M., Richards, John H.
core   +2 more sources

Daratumumab Treatment for Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP): A Case Report

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) is an immune‐mediated neuropathy featuring progressive weakness, sensory deficits, and areflexia. While corticosteroids, intravenous immunoglobulin, and plasmapheresis are effective first‐line immunotherapies, a subset of patients remains treatment‐refractory.
Xueyu Zhang   +8 more
wiley   +1 more source

Longitudinal minimal residual disease assessment in multiple myeloma patients in complete remission – results from the NMSG flow-MRD substudy within the EMN02/HO95 MM trial

open access: yesBMC Cancer, 2022
Background Multiple myeloma remains an incurable disease with multiple relapses due to residual myeloma cells in the bone marrow of patients after therapy.
Alexander Schmitz   +26 more
doaj   +1 more source

Mapping Functions in Health-Related Quality of Life: Mapping From Two Cancer-Specific Health-Related Quality-of-Life Instruments to EQ-5D-3L. [PDF]

open access: yes, 2015
BACKGROUND: Clinical trials in cancer frequently include cancer-specific measures of health but not preference-based measures such as the EQ-5D that are suitable for economic evaluation.
Brazier, JE   +4 more
core   +2 more sources

TRIM47 Regulates Energy Metabolism via Glycolytic Reprogramming to Drive Hepatocellular Carcinoma Progression and Represents an Efficient Therapeutic Target

open access: yesAdvanced Science, EarlyView.
This study identifies TRIM47 as a key driver of liver cancer progression by promoting glycolysis through ubiquitin‐mediated degradation of the gluconeogenic enzyme FBP1. TRIM47 enhances glucose uptake, lactate and ATP production, and tumor growth and metastasis.
Weijie Sun   +17 more
wiley   +1 more source

TNF receptor–related factor 3 inactivation promotes the development of intrahepatic cholangiocarcinoma through NF‐κB‐inducing kinase–mediated hepatocyte transdifferentiation

open access: yesHepatology, EarlyView., 2022
Abstract Background and Aims Intrahepatic cholangiocarcinoma (ICC) is a deadly but poorly understood disease, and its treatment options are very limited. The aim of this study was to identify the molecular drivers of ICC and search for therapeutic targets.
Yuto Shiode   +16 more
wiley   +1 more source

A proinflammatory response and polarized differentiation of stromal elements characterizes the murine myeloma bone marrow niche

open access: yesExperimental Hematology & Oncology
Background The bone marrow (BM) niche contains non-hematopoietic elements including mesenchymal stromal cells (MSC) and bone marrow endothelial cells (BMEC) which provide mechanical support, and control hematopoietic cell growth and differentiation ...
Hussein Ghamlouch   +11 more
doaj   +1 more source

NF-κB signaling and its relevance to the treatment of mantle cell lymphoma

open access: yesJournal of Hematology & Oncology, 2018
Mantle cell lymphoma is an aggressive subtype of non-Hodgkin B cell lymphoma that is characterized by a poor prognosis determined by Ki67 and Mantle Cell International Prognostic Index scores, but it is becoming increasingly treatable.
Swathi Balaji   +5 more
doaj   +1 more source

Is Circulating DNA and Tumor Cells in Myeloma the Way Forward?

open access: yesHemato, 2022
Multiple myeloma (MM) is the second deadliest hematological cancer. Despite the enormous innovation on MM treatment in the last decades, still 48% of patients die within 5 years after diagnosis. MM diagnosis and therapeutic strategy mainly rely on direct
Emilie Arnault Carneiro   +3 more
doaj   +1 more source

Home - About - Disclaimer - Privacy